As per DelveInsight’s estimates, among the 7MM, the US captured the highest market of high- and low-grade serous ovarian cancer of nearly USD 1,900 million in 2024, which is expected to increase due ...
If you haven’t been personally impacted by ovarian cancer, then you might not know that it isn’t just one disease; there are several types — and within that, subtypes — of ovarian cancer. The most ...
BOSTON--(BUSINESS WIRE)--Today, STAAR Low-Grade Serous Ovarian Cancer Foundation, Not These Ovaries, and Verastem Oncology announced the launch of the LGSOC Resource Guide, a unique resource designed ...
BOSTON--(BUSINESS WIRE)--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced results of the first-ever LGSOC ...
Avutometinib and defactinib target KRAS-mutated recurrent low-grade serous ovarian cancer, potentially becoming the first FDA-approved treatment for this specific cancer type. The NDA is supported by ...
New QIMR Berghofer research has found that low-dose aspirin may improve ovarian cancer survival. The study followed more than 900 Australian women newly-diagnosed with ovarian cancer, and asked them ...
In fertility clinics across India, doctors are seeing a new trend: women barely in their late 20s coming in with egg counts that resemble someone a decade older. For many, this discovery arrives after ...
A study has reported that the MEK inhibitor trametinib reduced the risk of disease progression or death by 52% compared to standard-of-care therapies for the treatment of low-grade serous ovarian ...
Researchers found low rates of patient involvement in first-line ovarian cancer treatment decisions in Europe and the US from 2017 to 2020 despite the increasing use of targeted therapies, like poly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results